Jasper Therapeutics, Inc.: Form 10-K/A for the period ended Dec 31, 2020
Filed with the SEC on May 24, 2021 and accepted by EDGAR at May 24, 2021, 16:14 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Operating income | 12 months2020-01-01 to 2020-12-31 | −$935.4k | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2020-01-01 to 2020-12-31 | $38.5k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2020-01-01 to 2020-12-31 | −$6.5m | us-gaap:NetIncomeLoss |
| Operating cash flow | 12 months2020-01-01 to 2020-12-31 | −$641.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2020-12-31 | $770.1k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-12-31 | $921.6k | us-gaap:AssetsCurrent |
| Total assets | At period end2020-12-31 | $101.3m | us-gaap:Assets |
| Current liabilities | At period end2020-12-31 | $269.5k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-12-31 | $16.9m | us-gaap:Liabilities |
| Shareholders' equity | At period end2020-12-31 | $5.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-21-028779. Last ingested by Listed: Nov 9, 2026, 17:50 ET. Listed shows no prices and gives no investment advice.